WilmerHale Advises PTC Therapeutics on up to $300 Million Royalty Sale

WilmerHale Advises PTC Therapeutics on up to $300 Million Royalty Sale

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.

WilmerHale advised PTC Therapeutics, Inc. (NASDAQ: PTCT), a global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines for patients with rare diseases, on the recent sale to Royalty Pharma plc (NASDAQ: RPRX) of its remaining royalty interest in Evrysdi®. PTC received an upfront payment of $240 million and may receive up to $60 million in sales-based milestone payments in the future. The agreement builds on the strategic partnership established in 2020 with Royalty Pharma.

The WilmerHale team advising PTC Therapeutics was led by George W. Shuster, Jr. and Nathan Moore and included Brian Johnson, Jeffries Oliver-Li, and Tim Kolankowski.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel